Mother and Daughter Hugging

Excitement is building for Corbus Pharmaceutical’s Phase 3 clinical trial testing the safety and effectiveness of their new drug lenabasum in dermatomyositis patients. Lenabasum works by resolving inflammation and scarring and stopping new inflammation from developing. One good thing about this treatment is that it does not suppress the inflammatory process, like prednisone and other myositis medications. It also has few side effects.

Results of earlier clinical trials in dermatomyositis, systemic sclerosis (scleroderma), and cystic fibrosis have been very promising. Additional clinical studies are being conducted and/or planned to confirm these early results and support the FDA’s approval process.

Recruitment for the Phase 3 trial  in dermatomyositis is expected to start by the end of this year, and TMA has received many questions about this drug, which we asked Corbus to respond to. Here are the company’s answers:

Is lenabasum only effective for the skin symptoms in dermatomyositis, or will it also be tested for the muscle weakness and pain of myositis?

The upcoming Phase 3 trial is testing the efficacy of lenabasum on many manifestations of DM, including muscle, skin, and lung involvement. Patients will be asked about symptoms such as pain and fatigue.

Are there plans to test it with children for juvenile dermatomyositis, and when?

The upcoming Phase 3 trial is for adults only. Depending on the results of this study, there is a potential for testing lenabasum in pediatric patients in the future. Adult patients who were diagnosed with JDM as children would be potentially eligible for the upcoming Phase 3 study.

Will it be tested with other forms of myositis, such as polymyositis, necrotizing myopathy, and antisynthetase syndrome (which often includes interstitial lung disease)?

At this time, there are no planned trials for these other forms of myositis.

Is lenabasum marijuana?

No, lenabasum was designed to have specific characteristics, such as decreased ability to enter the brain and increased binding to CB2 receptors, which are found on activated immune cells. The CB2 receptor is associated with turning on the resolution of inflammation and fibrosis. Lenabasum is expected to promote the resolution of inflammation without immunosuppression and without the psychotropic effects associated with marijuana.

6 comments on “Lenabasum questions answered”

  1. 1
    Lisa O'Rourke on December 18, 2018

    Have Dermatomyositis and ILD (Methotrexate ) ? If I would be a good candidate .

    1. 2
      Linda Kobert on December 19, 2018

      Corbus has not yet released the inclusion criteria for this clinical trial, so we don’t know if ILD is an exclusion. It is our understanding, however, that those who are on stable doses of DM medications, including immunosuppressives, will qualify. We will update this information as we receive it, so stay tuned.

  2. 3
    Gen on March 12, 2019

    I have DM and on prednisone how do I get on the waiting list to join the trial?

    1. 4
      Linda Kobert on March 13, 2019
  3. 5
    John Baker on August 29, 2019

    My wife suffers Diffuse Cutaneous Systemic Sclerosis. She was diagnosed right after the BP oil spill. We were just made aware that this disease is triggered by some environmental influence. Is that accurate? Also, are there any ways that my wife might participate in the study in New Orleans or Pensacola? If not, is there any way she can begin to take this drug for treatment under the umbrella of the clinical study?

    1. 6
      Linda Kobert on September 10, 2019

      Hello John,

      The clinical trial for lenabasum for systemic sclerosis is now fully enrolled. They expect to have results by next spring. If successful, the drug may be available soon after that. In the meantime, here is an email address to contact the company: You can let them know that Linda at The Myositis Association gave you the address.

Leave a Reply

Your email address will not be published. Required fields are marked *